Non-influence of lipid lowering therapy in atrial fibrillation recurrence

International Journal of Cardiology

Volumn 168, Issue 5, 2013, Pages 5006-5007

  Mehta, Kathan ^a   Grover, Peeyush M ^b   Shah, Neeraj ^c   Patel, Nileshkumar J ^c   Chothani, Ankit ^d   Singh, Vikas ^b   Savani, Ghanshyambhai T ^b   Deshmukh, Abhishek ^e   Rathod, Ankit ^f   Patel, Nilay ^g   Panaich, Sidakpal S ^g   Arora, Shilpkumar ^g   Nalluri, Nikhil ^c   Khalpada, Dhaval ^g   Bhalaria, Vipulkumar ^g   Parmar, Narendrasinh G ^g   Badheka, Apurva O ^b   Viles Gonzalez, Juan F ^b   Mitrani, Raul D ^b  

^a DREXEL UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^d WASHINGTON HOSPITAL CENTER   (United States)

^e UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g DETROIT MEDICAL CENTER   (United States)

Author keywords

Atrial fibrillation recurrence; Lipid lowering therapy; Non influence

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANTIARRHYTHMIC ACTIVITY; CORRELATION ANALYSIS; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; LETTER; POST HOC ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENCE RISK; RECURRENT DISEASE; SINUS RHYTHM; ATRIAL FIBRILLATION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ECHOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ATRIAL FIBRILLATION; ECHOCARDIOGRAPHY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84886395577     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.07.119     Document Type: Article

References (10)

1. C.I. Coleman, J. Kluger, and S. Bhavnani Association between statin use and mortality in patients with implantable cardioverter-defibrillators and left ventricular systolic dysfunction Heart Rhythm 5 2008 507 510
2. S.P. Bhavnani, C.I. Coleman, and C.M. White Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy Europace 10 2008 854 859
3. C.Y. Hung, C.H. Lin, E. Loh, C.T. Ting, and T.J. Wu CHADS(2) score, statin therapy, and risks of atrial fibrillation Am J Med 126 2013 133 140
4. L. Fauchier, N. Clementy, and D. Babuty Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled, trials Curr Opin Cardiol 28 2013 7 18
5. I.R. Hanna, B. Heeke, and H. Bush Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction Heart Rhythm 3 2006 881 886
6. A.O. Badheka, A. Rathod, and M.A. Kizilbash Impact of lipid-lowering therapy on outcomes in atrial fibrillation Am J Cardiol 105 2010 1768 1772
7. D. Wyse, A. Waldo, and J. DiMarco A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347 2002 1825
8. Y. Young-Xu, S. Jabbour, and R. Goldberg Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease Am J Cardiol 92 2003 1379 1383
9. J. Dernellis, and M. Panaretou Effect of C-reactive protein reduction on paroxysmal atrial fibrillation Am Heart J 150 2005 1064
10. C.J. Boos, R.A. Anderson, and G.Y. Lip Is atrial fibrillation an inflammatory disorder? Eur Heart J 27 2006 136 149